Play video

Why are recombinant antibodies important in flow cytometry?

Researchers and opinion leaders have considered a number of potential solutions to the so-called antibody-related reproducibility “crisis”. One is to transition from traditional monoclonal antibodies to recombinant antibodies*. 

So, what makes recombinant antibodies better and more effective than conventional hybridoma-derived antibodies?

We asked six experts from the flow cytometry and antibody community to share their opinion and experience with recombinant antibodies.  

Six experts. Six perspectivesOne opinion about recombinant antibodies.


“..approximately 50 % of all antibodies, that are sold, appear not to work.”

Andrew Bradbury, Ph.D. Chief Scientific Officer, Specifica Inc., United States


“…the whole field is suffering from poor specificity of antibodies.”

Karl Johan Malmberg, M.D., Ph.D., Professor of Immunology, Oslo University Hospital, Norway


“It´s crucially important for us, that we have high-quality reagents to minimize variation between experiments.”

James Hutchinson, MB BChir, Ph.D. Department of Surgery, University Hospital Regensburg, Germany


“We have seen that there is a huge advantage in terms of the background signal. ”

Anis Larbi, Ph.D., Head Flow Cytometry Platform, Principal Investigator Immunity and AgingA*STAR Institute, Singapore


“ I strongly believe that in the future, it will really pay off tolook at recombinant material.”

Dr. Susanne Heck, Head of Flow Cytometry Research Platform, BRC, Kings College London, United Kingdom


“…this is an important gain to improve panel precision and to limit the variability of results being produced.”

Joffrey de la Larichaudy, Ph.D., Deputy Director of QC, CELLforCURE, France